Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHANIE V BLANK

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1043211626
CMS profile
46868
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$86.27

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $71.20 1
Food and Beverage $15.07 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Intuitive Surgical, Inc. $71.20 1
GlaxoSmithKline, LLC. $15.07 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHANIE V BLANK

NPI 1043211626 · CMS profile ID 46868

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043211626?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043211626?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043211626?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEPHANIE V BLANK, NPI 1043211626, CMS profile ID 46868, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043211626?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $86.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $15.0712/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802821011 CMS
Intuitive Surgical, Inc. $71.2001/06/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853746513 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23.98 2
PY2021 $86.27 2
PY2022 $37.23 1
PY2025 $153.17 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $226,900.10 37
PY2024 Principal investigator $170,088.03 42
PY2023 Principal investigator $268,544.71 34
PY2022 Principal investigator $532,628.40 36
PY2021 Recipient $460.98 2
PY2021 Principal investigator $559,085.02 64
PY2020 Principal investigator $916,005.72 160
PY2019 Principal investigator $645,377.42 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,605.25 12/31/2024 Non-covered Recipient Entity
The Blavatnik Family- Chelsea Medical Center at Mount Sinai
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 1136415102
Principal investigator 1 Merck Sharp & Dohme LLC $6,794.71 12/31/2024 Non-covered Recipient Entity
The Blavatnik Family- Chelsea Medical Center at Mount Sinai
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer KEYNOTE-826 No dispute reported 06/30/2026 1136415106
Principal investigator 1 Merck Sharp & Dohme LLC $5,046.52 12/31/2024 Non-covered Recipient Entity
The Blavatnik Family- Chelsea Medical Center at Mount Sinai
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 1136430794
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 11/19/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530414
Principal investigator 1 Merck Sharp & Dohme LLC $22,327.50 10/31/2024 Non-covered Recipient Entity
The Blavatnik Family- Chelsea Medical Center at Mount Sinai
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 1136430790
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 10/29/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530420
Principal investigator 1 GlaxoSmithKline, LLC. $675.00 10/29/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530422
Principal investigator 1 GlaxoSmithKline, LLC. $425.00 10/29/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530424
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 10/25/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530550
Principal investigator 1 GlaxoSmithKline, LLC. $6,688.00 10/17/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530548
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 09/27/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127526778
Principal investigator 1 PFIZER INC. $1,050.00 09/26/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973258
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/19/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530418
Principal investigator 1 PFIZER INC. $750.00 09/18/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973252
Principal investigator 1 GlaxoSmithKline, LLC. $2,600.00 09/16/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127526780
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/16/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127526784
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 09/16/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530426
Principal investigator 1 GlaxoSmithKline, LLC. $675.00 09/16/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530544
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 09/06/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530430
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 09/06/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530540
Principal investigator 1 GlaxoSmithKline, LLC. $3,400.00 09/02/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530542
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 08/12/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530546
Principal investigator 1 PFIZER INC. $1,050.00 08/07/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973240
Principal investigator 1 PFIZER INC. $31,783.75 07/24/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973228
Principal investigator 1 PFIZER INC. $10,200.00 07/24/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973234
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 07/22/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127526776
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 07/17/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127526782
Principal investigator 1 PFIZER INC. $1,050.00 07/10/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973246
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 07/09/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127526774
Principal investigator 1 GlaxoSmithKline, LLC. $1,013.00 06/28/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530478
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 05/24/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530484
Principal investigator 1 PFIZER INC. $4,350.00 05/22/2024 Non-covered Recipient Entity
MOUNT SINAI MEDICAL CENTER
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1130973263
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 05/10/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127526786
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 05/03/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530538
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 05/02/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530428
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 04/30/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127530416
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 03/20/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530536
Principal investigator 1 GlaxoSmithKline, LLC. $4,776.30 02/16/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530486
Principal investigator 1 ImmunoGen, Inc. $1,050.00 02/09/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1155561523
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 01/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530480
Principal investigator 1 GlaxoSmithKline, LLC. $5,265.00 01/26/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A PHASE 1B/2 MULTICOHORT UMBRELLA STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1127530482
Principal investigator 1 GlaxoSmithKline, LLC. $9,788.00 01/18/2024 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1127526788